Find answers to all your questions on live GLAXO message board: Is GLAXO buy or sell? Should I buy GLAXO shares? Why are GLAXO shares falling? Should I invest in GLAXO stock?
Explained: Where does the world stand in the race for a coronavirus vaccine? The following is what we know about the race to deliver vaccines to help end the coronavirus pandemic, which has killed more than 1.8 million people worldwide
GLAXOSMITHKLINE. Short term as well as for long term investors can keep adding this stock on every correction for tgt 1590-1635-1678+ positional tgt 1800-2000+ mark in days to come
The next Covid vaccine challenge: Reassuring older Americans The drugmakers Sanofi and GlaxoSmithKline said on Friday that their vaccine seemed not to work well in older people, because the dosage was too low to generate a sufficient immune response in that population.
Sanofi-GlaxoSmithKline's experimental Covid vaccine fails in some older patients Instead, the companies said they planned to test a modified version of their vaccine in a smaller trial beginning in February. Rather than compare their candidate with a placebo, they said, it could be tested against a vaccine expected to be authorized by regulators for emergency use soon.
Markets like India added most to margins: Unilever Unilever, at the Morgan Stanley Global Consumer and Retail virtual conference on Tuesday, said the minority view was that the company needed to reset its margin in order to improve the market share.
Germany expects COVID-19 vaccine in Q1 2021 at the earliest The German government will cover the cost of the vaccines, while the cost of setting up the vaccination centres will be borne by the states and public and private health insurers where appropriate.
Neutral on GSK Pharma, target price Rs 1410: Motilal Oswal GlaxoSmithKline Pharmaceuticals Ltd., incorporated in the year 1924, is a Large Cap company (having a market cap of Rs 25389.73 Crore) operating in Pharmaceuticals sector.
GlaxoSmithKline Pharma Q2 results: Net profit declines 85% to Rs 76 cr Consolidated revenue from operations of the company stood at Rs 879.32 crore for the quarter under consideration. It was Rs 882.02 crore for the same period a year ago, it added.
GlaxoSmithKline Pharma Q2 net profit declines 85% to Rs 76.47 crore The company has recognised a financial impact of Rs 64.13 crore for the latest September quarter mainly to reflect the estimated realisable value of the assets, associated costs and impacts of reversal of provision on account of Zinetac recall, the filing said.
GSK, Sanofi to make 200 mn doses available for COVID-19 vaccine alliance COVAX aims to deliver 2 billion vaccine doses around the world by the end of 2021, and more than 180 nations have joined the plan. The United States and UK are leading a rush to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines.
GSK to widen COVID-19 antibody treatment trial after safety clearance The long-acting single injection will be tested on recently diagnosed high-risk cases for its ability to prevent hospitalisation, typically a life threatening disease stage.
US tariffs weigh on Europe stocks; Airbus dips The pan-European STOXX 600 was down 0.4%, with Airbus sliding 0.7% after Washington said it would maintain 15% tariffs on the planes and 25% tariffs on other European goods.
U.S. inks $1.5 billion deal with Moderna for 100 million doses of COVID-19 vaccine The United States in recent weeks has made deals to acquire hundreds of millions of doses of potential COVID-19 vaccines from several companies as part of its Operation Warp Speed program, which aims to deliver a vaccine in the country by the end of the year.
When it comes to a coronavirus vaccine, rich nations are first in line Although international groups and a number of nations are promising to make vaccines affordable and accessible to all, doses will likely struggle to keep up with demand in a world of roughly 7.8 billion people. The possibility wealthier countries will monopolize supply, a scenario that played out in the 2009 swine flu pandemic, has fueled concerns among poor nations and health advocates.
GlaxoSmithKline Pharmaceuticals Q1 net profit declines 2.38% to Rs 111 crore The company had posted a net profit of Rs 113.54 crore in the corresponding period previous fiscal, GlaxoSmithKline Pharmaceuticals said in a BSE filing.
Board Meetings Today: Maruti Suzuki, Bharti Airtel, SpiceJet, Dr Reddy’s Labs and Ceat GSK Pharma, Mahindra Lifespace, Manappuram Finance and TVS Motor will announce June quarter earnings today.
'Strict lockdowns' hit FMCG major Unilever's growth in India, other key markets Anglo-Dutch FMCG major Unilever on Thursday said strict lockdowns in key markets, including India, have impacted its business growth in the first half of 2020.
European Union in talks with Moderna, BioNtech, CureVac to secure Covid-19 vaccines The talks follow a deal reached in June by four EU states with AstraZeneca for the upfront purchase of 400 million doses of its potential Covid-19 vaccine, in principle available to all 27 EU nations. The information on the ongoing talks was shared by the European Commission, the EU executive arm, with EU health ministers at a meeting in Berlin on Thursday.
Indian pharma market contracts nearly 6% in Q1FY21 Chronic segment that includes drugs for cardiovascular, diabetes, and neuro saw a slump in sales in Q1FY21 due to pre-emptive buying in March
Immunity booster for your portfolio! Here's a list of 10 stocks to get through COVID times India's long-term fundamental stories for discretionary and consumption are intact, and sectors such as IT, Pharmaceuticals, Bank, Cement, Gas, Capital Goods, and insurance are expected to be the new leaders.
GSK is world's largest vaccine maker. Yet it has been tame with its COVID-19 strategy GSK is betting on its adjuvant technology to support companies developing COVID-19 vaccines.
Glaxosmithkline Pharmaceuticals Ltd. Q4 Cons: Net profit down -6% at Rs. 138.07 cr. Vs Rs. 146.81 cr. (YoY) and Revenue up 3.3% at Rs. 775.8 cr. Vs Rs. 750.81 cr. (YoY)
Board of Directors recommend a Dividend of Rs 40 per equity share of face value of Rs.10 eac...
GlaxoSmithKline Pharma Q4 net profit declines 6% to Rs 138 crore For the fiscal year ended March this year, the company posted a net profit of Rs 93.20 crore as against Rs 445.39 crore in the previous fiscal, the filing said.
Trade Setup for Tuesday: Top 15 things to know before Opening Bell Key support level for Nifty is placed at 8,700.57, followed by 8,577.88. If the index moves up, key resistance levels to watch out for are 9,052.12 and 9,280.98.
Hot Stocks | Glaxo Pharma, M&M, Tata Comm three buy ideas for short term In the week gone by, Nifty took out the crucial resistance of 9,390, which will interchange its role as immediate resistance.
Hot Stocks | Three stock ideas for the short term By surpassing the resistance of 8,600 in the previous week, Nifty also confirmed the bullish inverse head and shoulder pattern breakout on the daily line charts.
USFDA asks companies to remove ranitidine products; will Indian regulator review its stand? The USFDA is investigating presence N-Nitrosodimethylamine, a probable cancer causing impurity in ranitidine products.
Coronavirus pandemic | Pharma companies ask sales representatives to work from home India's largest drug maker Sun Pharma which has field force 9,500 plus covering over 400,000 doctors in every nook and corner of the country said it is encouraging employees in the field globally to work from home.
24 companies in BSE500 index reported net loss in Q3; what should you do with the stocks? Among the top 500 companies, over 20 companies turned loss-making in the December quarter, data from AceEquity showed
Sridhar Venkatesh appointed as GSK India MD, VP Venkatesh has more than 24 years of diverse experience in pharmaceuticals and healthcare, and has a strong track record of success in multiple roles within GSK, it added.
Ranitidine recall forces GSK to alter Indian market strategy GSK had initiated global voluntary recall of Ranitidine in September 2019, following reports of a probable cancer causing impurity called N‐nitrosodimethylamine (NDMA).
GSK announces sale of Vemagal plant; takes Rs 640 crore hit on account of Zinetac recall - Times of India Times of India brings the Latest & Top Breaking News on Politics and Current Affairs in India & around the World, Cricket, Sports, Business, Bollywood News and Entertainment, Science, Technology, Health & Fitness news & opinions from leading columnists.
The Times of India
Bad News for Pharmaceutical sector GlaxoSmithKline (GSK) Pharma - Bangalore
Yesterday night gave a very big Dinner in 5 star hotel to all Bangalore Employee & at the end of Dinner
GSK handed Termination Letter. With 6 months Salary Cheque.
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.